LifeStance Health Group (NASDAQ:LFST) Stock Price Up 3.5% on Analyst Upgrade

LifeStance Health Group, Inc. (NASDAQ:LFST)’s stock price rose 3.5% on Thursday after Barclays raised their price target on the stock from $13.00 to $15.00. Barclays currently has an overweight rating on the stock. LifeStance Health Group traded as high as $13.06 and last traded at $13.0660. Approximately 699,459 shares traded hands during trading, a decline of 80% from the average session volume of 3,475,673 shares. The stock had previously closed at $12.62.

Several other research analysts have also recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Canaccord Genuity Group lifted their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen lowered LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. KeyCorp upped their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Finally, The Goldman Sachs Group assumed coverage on shares of LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, LifeStance Health Group currently has an average rating of “Moderate Buy” and an average target price of $12.88.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 44,394 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $481,674.90. Following the transaction, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at approximately $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the sale, the insider owned 98,101,407 shares of the company’s stock, valued at approximately $1,041,836,942.34. This represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 14,671,917 shares of company stock worth $155,493,415 in the last ninety days. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC grew its position in shares of LifeStance Health Group by 19,952.6% during the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after acquiring an additional 3,791 shares during the period. KBC Group NV bought a new position in LifeStance Health Group in the 1st quarter worth $29,000. IFP Advisors Inc lifted its position in LifeStance Health Group by 316.5% during the second quarter. IFP Advisors Inc now owns 3,694 shares of the company’s stock valued at $40,000 after purchasing an additional 2,807 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after purchasing an additional 5,404 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in LifeStance Health Group during the second quarter valued at about $52,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Stock Performance

The business has a 50-day simple moving average of $11.60 and a 200 day simple moving average of $8.93. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a market cap of $5.07 billion, a PE ratio of 100.52 and a beta of 1.22.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $435.35 million for the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The business’s quarterly revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.01) EPS. Equities research analysts forecast that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.